{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:11:19Z","timestamp":1792595479993,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.radonc.2025.110866","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:13:22Z","timestamp":1742717602000},"page":"110866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evaluating the prognostic significance of artificial intelligence-delineated gross tumor volume and prostate volume measurements for prostate radiotherapy"],"prefix":"10.1016","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-6488","authenticated-orcid":false,"given":"Jenna","family":"Adleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2179","authenticated-orcid":false,"given":"James M.G.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-3434","authenticated-orcid":false,"given":"Ivan","family":"Buzurovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Urribarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Cail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Orio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-1700","authenticated-orcid":false,"given":"Leslie K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-5107","authenticated-orcid":false,"given":"Martin T.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110866_b0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"1","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0010","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.22.01856","article-title":"Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG Oncology RTOG 0232 randomized clinical trial","volume":"41","author":"Michalski","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2025.110866_b0015","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2025.110866_b0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"1","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose\u2013effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.110866_b0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2009.11.023","article-title":"The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy","volume":"79","author":"Aizer","year":"2011","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0055","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijrobp.2014.06.037","article-title":"Late urinary side effects 10years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals","volume":"90","author":"Keyes","year":"2014","journal-title":"Int J Radiat Oncol*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.brachy.2015.12.011","article-title":"Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy","volume":"15","author":"Eriguchi","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.110866_b0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.radonc.2020.09.023","article-title":"Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis","volume":"1","author":"Mendez","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0301-5629(98)00039-8","article-title":"Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging","volume":"24","author":"Tong","year":"1998","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.radonc.2025.110866_b0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2214\/AJR.19.22254","article-title":"Three-dimensional convolutional neural network for prostate MRI segmentation and comparison of prostate volume measurements by use of artificial neural network and ellipsoid formula","volume":"214","author":"Lee","year":"2020","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.radonc.2025.110866_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2023.07.029","article-title":"Assessing the feasibility of using artificial intelligence\u2013segmented dominant intraprostatic lesion for focal intraprostatic boost with external beam radiation therapy","volume":"118","author":"Tsui","year":"2024","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0085","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.240041","article-title":"AI-derived tumor volume from multiparametric MRI and outcomes in localized prostate cancer","volume":"313","author":"Yang","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2025.110866_b0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","article-title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","volume":"25","author":"Saha","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2025.110866_b0095","article-title":"Checklist for artificial intelligence in medical imaging (CLAIM): a guide for authors and reviewers. Radiology","volume":"2","author":"Mongan","year":"2020","journal-title":"Artif Intell"},{"key":"10.1016\/j.radonc.2025.110866_b0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","article-title":"nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation","volume":"18","author":"Isensee","year":"2021","journal-title":"Nat Methods"},{"key":"10.1016\/j.radonc.2025.110866_b0105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2008.04.056","article-title":"Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy","volume":"73","author":"Joseph","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110866_b0110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ijrobp.2009.08.040","article-title":"Predicting post\u2013external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI","volume":"78","author":"Fuchsj\u00e4ger","year":"2010","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2012.01.009","article-title":"Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy","volume":"84","author":"Riaz","year":"2012","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jmri.25335","article-title":"Haralick textural features on T2-weighted MRI are associated with biochemical recurrence following radiotherapy for peripheral zone prostate cancer","volume":"45","author":"Gnep","year":"2017","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2025.110866_b0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2214\/AJR.19.21836","article-title":"Prognostic value of pretreatment MRI in patients with prostate cancer treated with radiation therapy: a systematic review and meta-analysis","volume":"214","author":"Woo","year":"2019","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.radonc.2025.110866_b0130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.acra.2021.09.012","article-title":"Can pre-treatment quantitative multi-parametric MRI predict the outcome of radiotherapy in patients with prostate cancer?","volume":"29","author":"Chatterjee","year":"2022","journal-title":"Acad Radiol"},{"key":"10.1016\/j.radonc.2025.110866_b0135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ijrobp.2010.06.009","article-title":"Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy","volume":"81","author":"Roeloffzen","year":"2011","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"10.1016\/j.radonc.2025.110866_b0140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0145","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110866_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"npj Digit Med"},{"key":"10.1016\/j.radonc.2025.110866_b0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.radonc.2021.12.040","article-title":"Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation","volume":"167","author":"Kishan","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110866_b0160","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110866_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.brachy.2019.01.006","article-title":"Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A phase II randomized trial","author":"Tissaverasinghe","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.110866_b0170","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:18:42Z","timestamp":1748002722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"alternative-id":["S0167814025001616"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110866","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the prognostic significance of artificial intelligence-delineated gross tumor volume and prostate volume measurements for prostate radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110866"}}